A review of valproate in psychiatric practice
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Valproate (2-propylpentanoate) is available as valproic acid, sodium valproate and semisodium valproate. It has actions on dopamine, GABA and glutamate neurotransmission and intracellular signaling. Its main psychiatric use is to treat bipolar disorder. It has been used in other psychiatric disorders, including schizophrenia and borderline personality disorder, but data are insufficient to recommend this. In acute mania, valproate monotherapy has similar efficacy to antipsychotic drugs and lithium whereas the combination of valproate and an antipsychotic is more effective than either drug alone. In maintenance treatment of bipolar disorder, valproate monotherapy has comparable efficacy to olanzapine although placebo-controlled evidence is limited. Maintenance treatment with valproate and quetiapine or olanzapine is more efficacious than valproate alone when an acute episode responds to the combination. Common adverse effects of valproate include weight gain, gastrointestinal symptoms, sedation, tremor and mild elevation of hepatic enzymes. Serious hepatic toxicity is rare in adults. Many adverse effects are dose related and resolve with dose reduction. Valproate is teratogenic and specifically associated with neural tube defect. Preliminary evidence has linked in utero exposure to decreased verbal intelligence in the offspring. These effects, plus a probable increased risk of polycystic ovary syndrome, limit valproate's use in women of childbearing potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A., & Klein, P. S. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101287200 · Cited by 1,758 · cited 1×
“Valproate inhibits histidine decarboxylase, a negative regulator of gene expression, which may partly explain its effect on increasing GABA synthesis and its teratogenic effects [26].”
BackgroundOxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders
Hollander, E., Novotny, S., Hanratty, M., Yaffe, R., DeCaria, C. M., Aronowitz, B. R., & Mosovich, S. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300021 · Cited by 689
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678 · cited 1×
“conducted the only randomized placebocontrolled study of valproate as a maintenance agent in bipolar disorder [42].”
BackgroundViguera, A. C., Nonacs, R., Cohen, L. S., Tondo, L., Murray, A., & Baldessarini, R. J. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.2.179 · Cited by 488
Samrén, E. B., van Duijn, C. M., Koch, S., Hiilesmaa, V. K., Klepel, H., Bardy, A. H., Mannagetta, G. B., Deichl, A. W., Gaily, E., Granström, I. L., et al. (1997) · Epilepsia · doi:10.1111/j.1528-1157.1997.tb01480.x · Cited by 406 · cited 1×
“Valproate has a teratogenic risk (up to 11%) with first trimester use [96-99].”
BackgroundMeador, K., Reynolds, M. W., Crean, S., Fahrbach, K., & Probst, C. (2008) · Epilepsy Research · doi:10.1016/j.eplepsyres.2008.04.022 · Cited by 400 · cited 2×
“In a meta-analysis of pregnancy registries and cohort studies of first trimester exposure to antiepileptic drugs, valproate was the agent that was associated with the highest rate of major congenital abnormalities when administered in monotherapy [96].”
BackgroundTohen, M., Calabrese, J. R., Sachs, G. S., Banov, M. D., Detke, H. C., Risser, R., Baker, R. W., Chou, J. C.-Y., & Bowden, C. L. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.2.247 · Cited by 317 · cited 1×
“Olanzapine’s efficacy in maintenance treatment is supported by a 48-week placebo-controlled trial [44] and a 1-year trial against lithium [45].”
BackgroundSalloum, I. M., Cornelius, J. R., Daley, D. C., Kirisci, L., Himmelhoch, J. M., & Thase, M. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.1.37 · Cited by 271
Calabrese, J. R., Shelton, M. D., Rapport, D. J., Youngstrom, E. A., Jackson, K., Bilali, S., Ganocy, S. J., & Findling, R. L. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.11.2152 · Cited by 252 · cited 2×
“In one RCT, patients who had responded to combined treatment with lithium and valproate were randomized to a 20-month maintenance phase of lithium or valproate monotherapy [46].”
BackgroundKeck, P. E., & Calabrese, J. R. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1003 · Cited by 238
Cited by
Targeting the correct HDAC(s) to treat cognitive disorders
Fischer, A., Sananbenesi, F., Mungenast, A., & Tsai, L.-H. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.003 · Cited by 354
Adverse drug reactions induced by valproic acid
Nanau, R. M., & Neuman, M. G. (2013) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2013.06.012 · Cited by 321
The microbiome, immunity, and schizophrenia and bipolar disorder.
Dickerson, F., Severance, E., & Yolken, R. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.12.010 · Cited by 268
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171
Metadata
- Authors
- Haddad, P. M., Das, A., Ashfaq, M., & Wieck, A.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2009-05
- Volume
- 5
- Issue
- 5
- Pages
- 539-551
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2169871407
- Cited by
- 134
- References
- 19
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A review of valproate in psychiatric practice. https://app.cochat.ai/papers/10.1517/17425250902911455
- The paper
- Haddad, P. M., Das, A., Ashfaq, M., & Wieck, A. (2009). A review of valproate in psychiatric practice. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425250902911455
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.